Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

5 hrs ago | AmericanBankingNews.com

Gilead Sciences Given New $135.00 Price Target at Deutsche Bank

The firm currently has a "buy" rating on the stock. Deutsche Bank's price objective suggests a potential upside of 82.78% from the company's current price.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, Healthcare Industry

11 hrs ago | New Hampshire Public Radio -

Costly Hepatitis C Pill Shreds Drug Industry Sales Record

The launch of Sovaldi, the $1,000-a-day pill for hepatitis C, is shaping up as the most successful ever.

Comment?

Related Topix: Hepatitis, Medicine, Health, Food and Drug Administration, Biotech, Gilead Sciences, Healthcare Industry, Startups

15 hrs ago | Jerusalem Post

U.S. futures edge lower ahead of data, earnings; Dow Jones down 0.06%

Investing.com - U.S. stock futures pointed to a slightly lower open on Wednesday, as investors remained cautious ahead of U.S. economic reports, as well as a fresh batch of first quarter earnings reports to be released later in the day.

Comment?

Related Topix: Financial Markets, Apple, Startups, Google, Biotech, Medicine, Amgen, Healthcare Industry, Gilead Sciences

19 hrs ago | Seeking Alpha

Gilead Sciences' CEO Discusses Q1 2014 Results - Earnings Call Transcript

Welcome to the Gilead Sciences' first quarter 2014 earnings conference call. I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Marketing

23 hrs ago | MarketWatch

Gilead shares climb; AT&T, Amgen shares fall

Gilead Sciences Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall Street's quarterly earnings and revenue expectations and reporting a sales surge for its new hepatitis C treatment.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Gilead Sciences, Cable & Satellite, Telecom, ATT, Startups, Financial Markets, Hepatitis, Health

Tue Apr 22, 2014

The Campbell Reporter

Biz Break: Gilead's new hepatitis C drug produces huge sales in debut quarter

Today: Gilead Sciences demolishes earnings expectations thanks to powerful sales of breakthrough hepatitis C drug Sovaldi.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Intuitive Surgical, Netflix, Telecom, Juniper Networks, Computers

SFGate

Gilead Sciences' hepatitis C drug a smashing success

Orlando Chavez, fills a work station inside a mobile medical outreach van operated by the Berkeley Free Clinic, on Thursday April 10, 2014, in Berkeley, Calif., which does weekly on-the-street medical testing, including Hepatitis C. Chavez who was diagnosed with Hepatitis C in 1999 and underwent treatment successfully in 2004-2005, is now cured and ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Startups, CGI Pharmaceuticals, Healthcare Law, Law, Food and Drug Administration

Information Technology

Gilead Sciences Announces First Quarter 2014 Financial Results

Gilead Sciences, Inc. announced today its results of operations for the quarter ended March 31, 2014.

Comment?

Related Topix: Biotech, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Food and Drug Administration

SFGate

Biotech Company Gilead Just Destroyed All Expectations For Sales Of Its New Hepatitis C Drug

Gilead Sciences is among the big biotech companies that have seen their shares whipsaw in the recent sell-off in biotech stocks .

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Business News

TheStreet.com

Will Gilead Sciences (GILD) Earnings Boost The Stock In After-Market Trading?

The revenue reported in the company's first quarter earnings report surpassed analysts consensus quarterly revenue estimates of $3.9 billion.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Financial Markets, Warren Buffett

Mon Apr 21, 2014

BioSpace

FDA Accepts Gilead Sciences, Inc.'s Two NDAs For HIV Therapy

Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA FOSTER CITY, Calif.-- Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or "boosting" agent that increases ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Food and Drug Administration, Foster City, CA

Freshnews

Gilead Sciences' New Drug Applications for Cobicistat and...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Food and Drug Administration

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Sunrise wil... )--Werner Enterprises, Inc. , one of the nation's largest transportation and logistics companies, reported revenues and earnings for the first quarter ended... )--Link to Fitch Ratings' Report: Fitch US RMBS Servicer Snapshot Reporthttp://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=747112 Fitch Ratings has ... (more)

Comment?

Related Topix: HealthStream, Education, CBeyond, Aretta Communications, Cbeyond, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

AmericanBankingNews.com

Gilead Sciences (GILD) Scheduled to Post Quarterly Earnings on Tuesday

Gilead Sciences is scheduled to be announcing its Q114 earnings results on Tuesday, April 22nd.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

Sun Apr 20, 2014

GuruFocus.com

Weekly CFO Sells Highlight: AthenaHealth Inc, Gilead Sciences Inc, JPMorgan Chase & Co.

On 02/18/2014, CFO and SVP Timothy M Adams sold 30,000 shares at an average price of $194.58.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Banking, JP Morgan Chase , Startups, athenahealth, Application Service Providers, Software

Fri Apr 18, 2014

Lincoln Daily News

UnitedHealth: New hepatitis C drug costs far more than forecast

U nitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was "multiple" times what it had expected.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Wellpoint Health Networks, Insurance, Aetna, Goldman Sachs, Financial Services, Investment Services

Thu Apr 17, 2014

SFGate

Why Everyone Wants To Work In Biotech

Companies like Celgene, Biogen Idec, and Gilead Sciences all took top spots on our list of the Best Employers in America .

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Celgene, CGI Pharmaceuticals, Business News

Wed Apr 16, 2014

The Motley Fool

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides

One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Texas Government, Texas

Knowledge@Wharton

Sovaldi: Who's to Blame for the $1,000 a Day Cure?

When Foster City, Calif.-based Gilead Sciences was developing its hepatitis C treatment, Sovaldi, the medical community was wowed by the 90% cure rate the drug racked up in clinical trials.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, US Politics, US News, US House of Representatives, Henry Waxman, Democrat, Health, Startups

CNN

Stock Picks: Three Biotech Big-Caps to Look At

The recent biotech price correction may have sent some investors running for the hills, but not everyone is losing faith on the highly profitable sector.

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Gilead Sciences, Healthcare Industry, Startups, Search Engines, HIV/AIDS, Health

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••